<DOC>
	<DOC>NCT03053024</DOC>
	<brief_summary>The purpose of the study (retrospective and prospective) is to describe participant and disease characteristics and treatment pattern of Bortezomib treated mantle cell lymphoma (MCL) participants in China.</brief_summary>
	<brief_title>Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Participants that have been hospitalized for MCL after January 1st 2009. Biopsy proven MCL as evidenced by histology with either immunohistochemistry (IHC) or t(11,14) translocation Retrospective group: Participants who have finished BTZ treatment before the study initiation as judged by participating site physician If participant isn't accessible for oral or written informed consent, ICF can be waived after approved by the IRB Prospective group: Participants who are on BTZ at the time of study initiation or start BTZ after study initiation Participants with documented diagnosis of other cancers prior to or at the presence of the diagnosis of MCL Participants enrolled in interventional clinical trials of BTZ or any other drug for MCL Prospective group: Participants with contraindication listed in the prescribing information of BTZ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>